BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. Circulation 2018;137:1934-48. [PMID: 29254929 DOI: 10.1161/CIRCULATIONAHA.117.030423] [Cited by in Crossref: 73] [Cited by in F6Publishing: 95] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Matsumoto K, Suzuki K, Yoshida H, Magi M, Kaneko Y, Takeuchi T. Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis. Autoimmun Rev 2022;21:103160. [PMID: 35926769 DOI: 10.1016/j.autrev.2022.103160] [Reference Citation Analysis]
2 Watanabe R, Hashimoto M. Pathogenic role of monocytes/macrophages in large vessel vasculitis. Front Immunol 2022;13:859502. [DOI: 10.3389/fimmu.2022.859502] [Reference Citation Analysis]
3 Macaluso F, Marvisi C, Castrignanò P, Pipitone N, Salvarani C. Comparing treatment options for large vessel vasculitis. Expert Rev Clin Immunol 2022. [PMID: 35714219 DOI: 10.1080/1744666X.2022.2092098] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Watanabe R, Hashimoto M. Vasculitogenic T Cells in Large Vessel Vasculitis. Front Immunol 2022;13:923582. [DOI: 10.3389/fimmu.2022.923582] [Reference Citation Analysis]
5 Couette N, Jarjour W, Brammer JE, Simon Meara A. Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease. Front Oncol 2022;12:854499. [DOI: 10.3389/fonc.2022.854499] [Reference Citation Analysis]
6 Lu T, Liu Z, Guo D, Ma C, Duan L, He Y, Jia R, Guo C, Xing Z, Liu Y, Li T, He Y. Transcriptome-Based Dissection of Intracranial Aneurysms Unveils an “Immuno-Thermal” Microenvironment and Defines a Pathological Feature-Derived Gene Signature for Risk Estimation. Front Immunol 2022;13:878195. [DOI: 10.3389/fimmu.2022.878195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bond M, Tomelleri A, Buttgereit F, Matteson EL, Dejaco C. Looking ahead: giant-cell arteritis in 10 years time. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210963. [DOI: 10.1177/1759720x221096366] [Reference Citation Analysis]
8 Wang J, Dai X, Ma L, Wu S, Jin X, Ji Z, Chen H, Ma L, Ding Z, Jiang L, Kong X. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. Semin Arthritis Rheum 2022;55:152018. [PMID: 35523066 DOI: 10.1016/j.semarthrit.2022.152018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Watanabe R, Hashimoto M. Perspectives of JAK Inhibitors for Large Vessel Vasculitis. Front Immunol 2022;13:881705. [PMID: 35432355 DOI: 10.3389/fimmu.2022.881705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Aeschlimann FA, Yeung RSM, Laxer RM. An Update on Childhood-Onset Takayasu Arteritis. Front Pediatr 2022;10:872313. [DOI: 10.3389/fped.2022.872313] [Reference Citation Analysis]
11 Watanabe R, Hashimoto M. Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders. Front Aging Neurosci 2022;14:843305. [DOI: 10.3389/fnagi.2022.843305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hur B, Koster MJ, Jang JS, Weyand CM, Warrington KJ, Sung J. Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms. Arthritis Rheumatol 2022. [PMID: 35403833 DOI: 10.1002/art.42138] [Reference Citation Analysis]
13 Robert M, Miossec P, Hot A. The Th17 Pathway in Vascular Inflammation: Culprit or Consort? Front Immunol 2022;13:888763. [DOI: 10.3389/fimmu.2022.888763] [Reference Citation Analysis]
14 Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, Ruan G, Bai X. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology 2022;105:108517. [DOI: 10.1016/j.intimp.2022.108517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Singh K, Rathore U, Rai MK, Behera MR, Jain N, Ora M, Bhadauria D, Sharma S, Pande G, Gambhir S, Nath A, Kumar S, Sharma A, Agarwal V, Misra DP. Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease. JIR 2022;Volume 15:1521-41. [DOI: 10.2147/jir.s355881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
16 Jin K, Parreau S, Warrington KJ, Koster MJ, Berry GJ, Goronzy JJ, Weyand CM. Regulatory T Cells in Autoimmune Vasculitis. Front Immunol 2022;13:844300. [DOI: 10.3389/fimmu.2022.844300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Koster MJ, Crowson CS, Giblon RE, Jaquith JM, Duarte-García A, Matteson EL, Weyand CM, Warrington KJ. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis 2022:annrheumdis-2021-221961. [PMID: 35190385 DOI: 10.1136/annrheumdis-2021-221961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
18 Sandovici M, van der Geest N, van Sleen Y, Brouwer E. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open 2022;8:e001652. [PMID: 35149602 DOI: 10.1136/rmdopen-2021-001652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Vieira M, Régnier P, Maciejewski-Duval A, Le Joncour A, Darasse-Jèze G, Rosenzwajg M, Klatzmann D, Cacoub P, Saadoun D. Interferon signature in giant cell arteritis aortitis. J Autoimmun 2022;127:102796. [PMID: 35123212 DOI: 10.1016/j.jaut.2022.102796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
20 Regola F, Uzzo M, Toniati P, Trezzi B, Sinico RA, Franceschini F. Novel Therapies in Takayasu Arteritis. Front Med (Lausanne) 2021;8:814075. [PMID: 35096902 DOI: 10.3389/fmed.2021.814075] [Reference Citation Analysis]
21 Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, Grayson PC, McAdoo SP, Mason JC, Owen C, Weyand CM, Youngstein T, Dhaun N. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. [PMID: 34992251 DOI: 10.1038/s41572-021-00327-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
22 Ciccia F, Macaluso F, Mauro D, Nicoletti GF, Croci S, Salvarani C. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? The Lancet Rheumatology 2021;3:e874-85. [DOI: 10.1016/s2665-9913(21)00253-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Solimando AG, Vacca A, Dammacco F. Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications. Clin Exp Med 2021. [PMID: 34741677 DOI: 10.1007/s10238-021-00770-4] [Reference Citation Analysis]
24 Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 2021. [PMID: 34729652 DOI: 10.1007/s10067-021-05973-4] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
25 Li HY, Xu JN, Shuai ZW. Cellular signaling pathways of T cells in giant cell arteritis. J Geriatr Cardiol 2021;18:768-78. [PMID: 34659383 DOI: 10.11909/j.issn.1671-5411.2021.09.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Hu H, Keat K. Myeloperoxidase and associated lung disease: Review of the latest developments. Int J Rheum Dis 2021;24:1460-6. [PMID: 34498802 DOI: 10.1111/1756-185X.14213] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Jin K, Wen Z, Wu B, Zhang H, Qiu J, Wang Y, Warrington KJ, Berry GJ, Goronzy JJ, Weyand CM. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. J Clin Invest 2021;131:136042. [PMID: 32960812 DOI: 10.1172/JCI136042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
28 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Di Benedetto P, Ruscitti P, Berardicurti O, Panzera N, Grazia N, Di Vito Nolfi M, Di Francesco B, Navarini L, Maurizi A, Rucci N, Teti AM, Zazzeroni F, Guggino G, Ciccia F, Dolo V, Alesse E, Cipriani P, Giacomelli R. Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. Arthritis Res Ther 2021;23:213. [PMID: 34391476 DOI: 10.1186/s13075-021-02587-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
30 Sener S, Basaran O, Ozen S. Wind of Change in the Treatment of Childhood-Onset Takayasu Arteritis: a Systematic Review. Curr Rheumatol Rep 2021;23:68. [PMID: 34218346 DOI: 10.1007/s11926-021-01032-8] [Reference Citation Analysis]
31 Ren HM, Lukacher AE, Rahman ZSM, Olsen NJ. New developments implicating IL-21 in autoimmune disease. J Autoimmun 2021;122:102689. [PMID: 34224936 DOI: 10.1016/j.jaut.2021.102689] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Zhu KJ, Yang PD, Xu Q. Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report. Front Immunol 2021;12:695768. [PMID: 34248994 DOI: 10.3389/fimmu.2021.695768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sebastian A, Tomelleri A, Dasgupta B. Current and innovative therapeutic strategies for the treatment of giant cell arteritis. Expert Opinion on Orphan Drugs 2021;9:161-73. [DOI: 10.1080/21678707.2021.1932458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Roger I, Milara J, Montero P, Cortijo J. The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension. Int J Mol Sci 2021;22:4980. [PMID: 34067108 DOI: 10.3390/ijms22094980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bursi R, Cafaro G, Perricone C, Riccucci I, Calvacchi S, Gerli R, Bartoloni E. Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future. Front Pharmacol 2021;12:635663. [PMID: 33854436 DOI: 10.3389/fphar.2021.635663] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
36 Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Innate and Adaptive Immunity in Giant Cell Arteritis. Front Immunol 2020;11:621098. [PMID: 33717054 DOI: 10.3389/fimmu.2020.621098] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
37 Li J, Li M, Tian X, Zeng X. Tofacitinib in patients with refractory Takayasu's arteritis. Rheumatology (Oxford) 2020;59:e95-8. [PMID: 32591815 DOI: 10.1093/rheumatology/keaa281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
38 Moura RA, Fonseca JE. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. Front Med (Lausanne) 2020;7:607725. [PMID: 33614673 DOI: 10.3389/fmed.2020.607725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
39 Zhang B, Lin L, Yuan F, Song G, Chang Q, Wu Z, Miao Z, Mo D, Huo X, Liu A. Clinical application values of neutrophil-to-lymphocyte ratio in intracranial aneurysms. Aging (Albany NY) 2021;13:5250-62. [PMID: 33526720 DOI: 10.18632/aging.202445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Harrington R, Al Nokhatha SA, Conway R. Biologic Therapies for Giant Cell Arteritis. Biologics 2021;15:17-29. [PMID: 33442231 DOI: 10.2147/BTT.S229662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
41 Li Y, Altemus J, Lightner AL. Mesenchymal stem cells and acellular products attenuate murine induced colitis. Stem Cell Res Ther 2020;11:515. [PMID: 33256827 DOI: 10.1186/s13287-020-02025-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
42 Jia E, Yan G, Xiao M, Geng H, Wei J, Zhang J. Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib. Dermatol Ther 2020;33:e14470. [PMID: 33112475 DOI: 10.1111/dth.14470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Hellmich B, Águeda AF, Monti S, Luqmani R. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Curr Rheumatol Rep 2020;22:84. [PMID: 33044642 DOI: 10.1007/s11926-020-00964-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
44 Palmowski A, Buttgereit F. Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis. Curr Rheumatol Rep 2020;22:85. [PMID: 33047263 DOI: 10.1007/s11926-020-00961-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Front Immunol 2020;11:587089. [PMID: 33072134 DOI: 10.3389/fimmu.2020.587089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
46 Sellmayr M, Hernandez Petzsche MR, Ma Q, Krüger N, Liapis H, Brink A, Lenz B, Angelotti ML, Gnemmi V, Kuppe C, Kim H, Bindels EMJ, Tajti F, Saez-Rodriguez J, Lech M, Kramann R, Romagnani P, Anders HJ, Steiger S. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease. J Am Soc Nephrol 2020;31:2773-92. [PMID: 32938648 DOI: 10.1681/ASN.2020040523] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
47 Lü L, Yakoumatos L, Ren J, Duan X, Zhou H, Gu Z, Mohammed M, Uriarte SM, Liang S, Scott DA, Lamont RJ, Wang H. JAK3 restrains inflammatory responses and protects against periodontal disease through Wnt3a signaling. FASEB J 2020;34:9120-40. [PMID: 32433819 DOI: 10.1096/fj.201902697RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
48 Zhang H, Watanabe R, Berry GJ, Nadler SG, Goronzy JJ, Weyand CM. CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis. J Am Coll Cardiol 2019;73:1811-23. [PMID: 30975299 DOI: 10.1016/j.jacc.2019.01.049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
49 Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica. Drugs Aging 2019;36:1015-26. [PMID: 31493201 DOI: 10.1007/s40266-019-00705-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
50 Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019;58:i43-54. [PMID: 30806709 DOI: 10.1093/rheumatology/key276] [Cited by in Crossref: 92] [Cited by in F6Publishing: 130] [Article Influence: 46.0] [Reference Citation Analysis]
51 Yamamura Y, Matsumoto Y, Asano Y, Katayama Y, Hayashi K, Ohashi K, Morishita M, Watanabe H, Takano-Narazaki M, Sada KE, Wada J. Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib. Rheumatol Adv Pract 2020;4:rkz050. [PMID: 32016168 DOI: 10.1093/rap/rkz050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
52 Watanabe R, Maeda T, Zhang H, Berry GJ, Zeisbrich M, Brockett R, Greenstein AE, Tian L, Goronzy JJ, Weyand CM. MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis. Circ Res 2018;123:700-15. [PMID: 29970365 DOI: 10.1161/CIRCRESAHA.118.313206] [Cited by in Crossref: 38] [Cited by in F6Publishing: 58] [Article Influence: 12.7] [Reference Citation Analysis]
53 Espinoza GM, Liu JL. Orbital Vasculitides-Differential Diagnosis. Curr Rheumatol Rep 2019;21:54. [PMID: 31486966 DOI: 10.1007/s11926-019-0853-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol 2019;10:212. [PMID: 30930775 DOI: 10.3389/fphar.2019.00212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 53] [Article Influence: 13.7] [Reference Citation Analysis]
55 Weyand CM, Watanabe R, Zhang H, Akiyama M, Berry GJ, Goronzy JJ. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol 2019;206:33-41. [PMID: 30772599 DOI: 10.1016/j.clim.2019.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
56 Low C, Conway R. Current advances in the treatment of giant cell arteritis: the role of biologics. Ther Adv Musculoskelet Dis 2019;11:1759720X19827222. [PMID: 30800174 DOI: 10.1177/1759720X19827222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
57 Watanabe R, Hilhorst M, Zhang H, Zeisbrich M, Berry GJ, Wallis BB, Harrison DG, Giacomini JC, Goronzy JJ, Weyand CM. Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight 2018;3:123047. [PMID: 30333306 DOI: 10.1172/jci.insight.123047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
58 van der Geest KSM, Sandovici M, van Sleen Y, Sanders JS, Bos NA, Abdulahad WH, Stegeman CA, Heeringa P, Rutgers A, Kallenberg CGM, Boots AMH, Brouwer E. Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? Arthritis Rheumatol 2018;70:1366-76. [PMID: 29648680 DOI: 10.1002/art.40520] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
59 Stawski L, Trojanowska M. Oncostatin M and its role in fibrosis. Connect Tissue Res 2019;60:40-9. [PMID: 30056769 DOI: 10.1080/03008207.2018.1500558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]